Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530101 · ClinicalTrials.gov registry record · Phase 1
The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00530101 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 3 participants.
The verdict
NCT00530101, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.
Interventions
- DRUG Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530101
The ClinicalTrials.gov registry entry for NCT00530101 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxorubicin is the first listed.
NCT00530101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530101 about?
NCT00530101 is a clinical study titled "The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity". The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Mill...
What is the current status of trial NCT00530101?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2004-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00530101?
The interventions under investigation include: Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00530101?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.